Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AryoTrust + docetaxel + doxorubicin + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Aryogen Biopharma
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AryoTrust + docetaxel + doxorubicin + cyclophosphamide is a neoadjuvant chemotherapy regimen developed by AryoGen Pharmed Co. for the treatment of HER2-positive breast cancer. The regimen consists of a sequential administration schedule: four 14-day cycles of doxorubicin (an anthracycline topoisomerase II inhibitor) and cyclophosphamide (a DNA alkylating agent), followed by four 21-day cycles of AryoTrust (a biosimilar trastuzumab) and docetaxel (a taxane microtubule stabilizer). AryoTrust is a recombinant humanized monoclonal antibody that targets the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting tumor cell proliferation and survival. This combination is currently being evaluated in a Phase III clinical trial (NCT03425656) to compare its efficacy and safety against the reference regimen containing Herceptin in the neoadjuvant setting.
- Other names
- AryoGen Trastuzumab
02
Targets
DNATOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on AryoTrust + docetaxel + doxorubicin + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AryoTrust + docetaxel + doxorubicin + cyclophosphamide.